Godavari Drugs (BOM:530317) Cyclically Adjusted Revenue per Share: ₹184.91 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:530317 Godavari Drugs Ltd BOM:530317
60 GF Score
Price ₹109.00
GF Value ₹75.29
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Godavari Drugs Cyclically Adjusted Revenue per Share?

Godavari Drugs BOM:530317 -3.87% 60 Cyclically Adjusted Revenue per Share is ₹184.91 as of Jun. 2026. GuruFocus rates BOM:530317 with a GF Score™ of 60/100 and a GF Value™ of ₹75.29 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Godavari Drugs's adjusted revenue per share for the three months ended in Jun. 2026 was ₹27.727. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹184.91 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Godavari Drugs's average Cyclically Adjusted Revenue Growth Rate was 3.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 14.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Godavari Drugs was 22.40% per year. The lowest was 8.40% per year. And the median was 14.70% per year.

As of today (2026-09-09), Godavari Drugs's current stock price is ₹109.00. Godavari Drugs's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹184.91. Godavari Drugs's Cyclically Adjusted PS Ratio of today is 0.59.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Godavari Drugs was 0.79. The lowest was 0.39. And the median was 0.57.


Godavari Drugs  (BOM:530317) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Godavari Drugs's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=109.00/184.91
=0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Godavari Drugs was 0.79. The lowest was 0.39. And the median was 0.57.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Godavari Drugs Cyclically Adjusted Revenue per Share Related Terms


Godavari Drugs Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Godavari Drugs's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Godavari Drugs Cyclically Adjusted Revenue per Share Chart

Godavari Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 117.37 143.91 168.85 177.06 183.36

Godavari Drugs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 179.08 181.79 182.41 183.36 184.91

BOM:530317 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Godavari Drugs's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Godavari Drugs Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Godavari Drugs's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Godavari Drugs's Cyclically Adjusted PS Ratio falls into.


BOM:530317
60GF Score
Godavari Drugs Ltd BOM:530317
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Godavari Drugs Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Godavari Drugs's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=27.727/167.3573*167.3573
=27.727

Current CPI (Jun. 2026) = 167.3573.

Godavari Drugs Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 27.118 105.961 42.831
201612 20.928 105.196 33.295
201703 21.296 105.196 33.880
201706 16.115 107.109 25.180
201709 23.386 109.021 35.900
201712 19.138 109.404 29.276
201803 27.493 109.786 41.910
201806 21.447 111.317 32.244
201809 23.781 115.142 34.565
201812 30.535 115.142 44.382
201903 32.553 118.202 46.090
201906 29.339 120.880 40.620
201909 30.535 123.175 41.488
201912 34.511 126.235 45.753
202003 32.833 124.705 44.063
202006 34.129 127.000 44.974
202009 40.981 130.118 52.710
202012 43.910 130.889 56.144
202103 43.834 131.771 55.672
202106 58.920 134.084 73.541
202109 51.289 135.847 63.186
202112 44.848 138.161 54.325
202203 59.033 138.822 71.168
202206 56.335 142.347 66.233
202209 53.976 144.661 62.444
202212 52.086 145.763 59.802
202303 49.707 146.865 56.643
202306 47.200 150.280 52.564
202309 52.674 151.492 58.190
202312 57.206 152.924 62.605
202403 51.506 153.035 56.327
202406 42.858 155.789 46.041
202409 34.747 157.882 36.832
202412 39.277 158.323 41.518
202503 33.981 157.552 36.096
202506 31.576 159.755 33.079
202509 35.419 162.289 36.525
202512 29.575 163.281 30.313
202603 42.133 164.272 42.924
202606 27.727 167.357 27.727

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹184.91 mean?
Godavari Drugs (BOM:530317) has a Cyclically Adjusted Revenue per Share of ₹184.91 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Godavari Drugs and its competitors.
Is Godavari Drugs' Cyclically Adjusted Revenue per Share too high?
Godavari Drugs' current Cyclically Adjusted Revenue per Share is ₹184.91. Overall, Godavari Drugs has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Godavari Drugs' Cyclically Adjusted Revenue per Share compare to ZTS?
Godavari Drugs' Cyclically Adjusted Revenue per Share of ₹184.91 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Godavari Drugs and its competitors. Godavari Drugs's current Cyclically Adjusted Revenue per Share is ₹184.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Godavari Drugs stock overvalued right now?
Based on GuruFocus' analysis, Godavari Drugs (BOM:530317) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹75.29, compared to a current price of ₹109.00 — trading 44.8% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹184.91. Godavari Drugs' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Godavari Drugs (BOM:530317), the current Cyclically Adjusted Revenue per Share is ₹184.91 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Godavari Drugs (BOM:530317) Overvalued in 2026?

Based on GuruFocus' analysis, Godavari Drugs stock appears to be overvalued. The current stock price of ₹109.00 is trading 44.8% above its estimated GF Value™ of ₹75.29. GuruFocus considers Godavari Drugs to be Significantly Overvalued.

Key valuation signals for BOM:530317:

  • Cyclically Adjusted Revenue per Share: ₹184.91
  • GF Value™: ₹75.29 vs. price of ₹109.00 (44.8% above fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the BOM:530317 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Godavari Drugs Business Description

Address Sardar Patel Road, 1-8-303/34, Mayfair, 1st Floor, Secunderabad, TG, IND, 500 003
Godavari Drugs Ltd is an India-based pharmaceutical company. It is principally engaged in manufacturing of APl's, intermediates and fine chemicals,. The firm's product includes Ciprofloxacin hydrochloride, ciprofloxacin, ciprofloxacin lactate, ciprofloxacin lactate, and Others. The company operates only one segment which is the manufacture and sale of Active Pharmaceutical Ingredients (API) and its intermediates.
60GF Score

Get the complete analysis for BOM:530317

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹109.00
Price
₹75.29
GF Value